Hepatitis C therapy with long term remission after renal transplantation

S. Bunnapradist, F. Fabrizi, J. Vierling, Paul Martin, A. Moudgil, E. Kamil, S. Jordan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatitis C virus infection (HCV) is common in patients with end-stage renal disease (ESRD) and long observation periods have shown the detrimental effect of HCV infection on patient and graft survival after renal transplantation. At present, interferon is the most important agent for the treatment of hepatitis C in ESRD; however, limited information exists concerning the long-term response of patients who undergo renal transplantation after successful antiviral therapy. We describe the evolution of HCV infection in a dialysis patient with hepatitis C who was successfully treated with interferon alpha and then underwent renal transplantation. He received aggressive immunosuppression during the induction phase and for allograft rejection; however, regular screening showed complete absence of biochemical and virological relapse of HCV over a 6-year post-transplantation period. We conclude that interferon can offer excellent response in selected dialysis patients with hepatitis C. Alternative strategies with newer antiviral agents are currently under active investigation.

Original languageEnglish
Pages (from-to)1189-1193
Number of pages5
JournalInternational Journal of Artificial Organs
Volume25
Issue number12
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Hepatitis C
Interferons
Viruses
Kidney Transplantation
Virus Diseases
Hepacivirus
Dialysis
Antiviral Agents
Antiviral agents
Chronic Kidney Failure
Transplantation (surgical)
Therapeutics
Interferon-alpha
Grafts
Allografts
Graft Survival
Screening
Infection
Immunosuppression
Transplantation

Keywords

  • Hepatitis C
  • Interferon
  • Renal transplant

ASJC Scopus subject areas

  • Biophysics

Cite this

Bunnapradist, S., Fabrizi, F., Vierling, J., Martin, P., Moudgil, A., Kamil, E., & Jordan, S. (2002). Hepatitis C therapy with long term remission after renal transplantation. International Journal of Artificial Organs, 25(12), 1189-1193.

Hepatitis C therapy with long term remission after renal transplantation. / Bunnapradist, S.; Fabrizi, F.; Vierling, J.; Martin, Paul; Moudgil, A.; Kamil, E.; Jordan, S.

In: International Journal of Artificial Organs, Vol. 25, No. 12, 01.12.2002, p. 1189-1193.

Research output: Contribution to journalArticle

Bunnapradist, S, Fabrizi, F, Vierling, J, Martin, P, Moudgil, A, Kamil, E & Jordan, S 2002, 'Hepatitis C therapy with long term remission after renal transplantation', International Journal of Artificial Organs, vol. 25, no. 12, pp. 1189-1193.
Bunnapradist S, Fabrizi F, Vierling J, Martin P, Moudgil A, Kamil E et al. Hepatitis C therapy with long term remission after renal transplantation. International Journal of Artificial Organs. 2002 Dec 1;25(12):1189-1193.
Bunnapradist, S. ; Fabrizi, F. ; Vierling, J. ; Martin, Paul ; Moudgil, A. ; Kamil, E. ; Jordan, S. / Hepatitis C therapy with long term remission after renal transplantation. In: International Journal of Artificial Organs. 2002 ; Vol. 25, No. 12. pp. 1189-1193.
@article{f19e6fb99b414210be256774658f5a7e,
title = "Hepatitis C therapy with long term remission after renal transplantation",
abstract = "Hepatitis C virus infection (HCV) is common in patients with end-stage renal disease (ESRD) and long observation periods have shown the detrimental effect of HCV infection on patient and graft survival after renal transplantation. At present, interferon is the most important agent for the treatment of hepatitis C in ESRD; however, limited information exists concerning the long-term response of patients who undergo renal transplantation after successful antiviral therapy. We describe the evolution of HCV infection in a dialysis patient with hepatitis C who was successfully treated with interferon alpha and then underwent renal transplantation. He received aggressive immunosuppression during the induction phase and for allograft rejection; however, regular screening showed complete absence of biochemical and virological relapse of HCV over a 6-year post-transplantation period. We conclude that interferon can offer excellent response in selected dialysis patients with hepatitis C. Alternative strategies with newer antiviral agents are currently under active investigation.",
keywords = "Hepatitis C, Interferon, Renal transplant",
author = "S. Bunnapradist and F. Fabrizi and J. Vierling and Paul Martin and A. Moudgil and E. Kamil and S. Jordan",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "25",
pages = "1189--1193",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "12",

}

TY - JOUR

T1 - Hepatitis C therapy with long term remission after renal transplantation

AU - Bunnapradist, S.

AU - Fabrizi, F.

AU - Vierling, J.

AU - Martin, Paul

AU - Moudgil, A.

AU - Kamil, E.

AU - Jordan, S.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Hepatitis C virus infection (HCV) is common in patients with end-stage renal disease (ESRD) and long observation periods have shown the detrimental effect of HCV infection on patient and graft survival after renal transplantation. At present, interferon is the most important agent for the treatment of hepatitis C in ESRD; however, limited information exists concerning the long-term response of patients who undergo renal transplantation after successful antiviral therapy. We describe the evolution of HCV infection in a dialysis patient with hepatitis C who was successfully treated with interferon alpha and then underwent renal transplantation. He received aggressive immunosuppression during the induction phase and for allograft rejection; however, regular screening showed complete absence of biochemical and virological relapse of HCV over a 6-year post-transplantation period. We conclude that interferon can offer excellent response in selected dialysis patients with hepatitis C. Alternative strategies with newer antiviral agents are currently under active investigation.

AB - Hepatitis C virus infection (HCV) is common in patients with end-stage renal disease (ESRD) and long observation periods have shown the detrimental effect of HCV infection on patient and graft survival after renal transplantation. At present, interferon is the most important agent for the treatment of hepatitis C in ESRD; however, limited information exists concerning the long-term response of patients who undergo renal transplantation after successful antiviral therapy. We describe the evolution of HCV infection in a dialysis patient with hepatitis C who was successfully treated with interferon alpha and then underwent renal transplantation. He received aggressive immunosuppression during the induction phase and for allograft rejection; however, regular screening showed complete absence of biochemical and virological relapse of HCV over a 6-year post-transplantation period. We conclude that interferon can offer excellent response in selected dialysis patients with hepatitis C. Alternative strategies with newer antiviral agents are currently under active investigation.

KW - Hepatitis C

KW - Interferon

KW - Renal transplant

UR - http://www.scopus.com/inward/record.url?scp=0346665820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346665820&partnerID=8YFLogxK

M3 - Article

C2 - 12518964

AN - SCOPUS:0346665820

VL - 25

SP - 1189

EP - 1193

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 12

ER -